Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. This phase I/II trial is studying the side effects and best
dose of temsirolimus when given together with erlotinib and to see how well they work in
treating patients with recurrent malignant glioma.